CD274 and cancer: In addition, Siglec-15 was recently recognized as an immune suppressive receptor in cancer, and found to be exclusively expressed with programmed cell death ligand 1 (PD-L1) (16, 17); this implies that it can be an alternative target for non-responders to PD-1 therapy.